SPOTLIGHT -
Review of AENEAS Trial and Similar Agents
Experts in cancer care review the phase 3 AENEAS trial with aumolertinib and the cost-effectiveness.
Read More
EGFR-Targeted TKIs in NSCLC and Cost
Mark Socinski, MD, Gilberto Lopes, MD, and Jack West, MD, provide an overview of the role of EGFR-targeted TKIs in NSCLC and the costs.
Impact of Payers on the Costs of Drugs
Jack West, MD, and Gilberto Lopes, MD, share their thoughts on the impact of payers when dealing with the cost of treatments.
Personalized Therapies Based on Innovation and Affordability
Gilberto Lopes, MD, and Afsaneh Barzi, MD, PhD, discuss personalized treatment plans based on innovative therapies and affordability.
Role of Financial Toxicity on Treatment Decisions
Experts in various specialties of oncology management share their insights on the role of financial toxicity on making treatment decisions for patients.
Definition of Financial Toxicity
Jack West, MD, Gilberto Lopes, MD, and Afsaneh Barzi, MD, PhD, provide a definition for financial toxicity.
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)